{"id":408052,"date":"2019-07-11T06:24:01","date_gmt":"2019-07-11T06:24:01","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=408052"},"modified":"2019-07-11T06:24:01","modified_gmt":"2019-07-11T06:24:01","slug":"gene-therapy-market-is-anticipated-to-grasp-4402-million-by-2023-with-recording-a-cagr-of-333-allied-market-research","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/gene-therapy-market-is-anticipated-to-grasp-4402-million-by-2023-with-recording-a-cagr-of-333-allied-market-research_408052.html","title":{"rendered":"Gene Therapy Market Is Anticipated to Grasp $4,402 Million By 2023, With Recording a CAGR of 33.3% | Allied Market Research"},"content":{"rendered":"
\"Gene<\/a><\/p>\n
\n
Gene Therapy Market <\/div>\n<\/div>\n<\/div>\n
Increase in awareness in regards with the benefits of using gene therapy as compared to conventional therapy for the treatment of various diseases and government support to promote gene therapy related research are the major driving factors that are projected to boost the market growth<\/div>\n

Gene Therapy Market<\/strong><\/a> is expected to reach $4,402 million by 2023 from $784 million in 2017, registering a CAGR of 33.3%.<\/p>\n

The growth of the global gene therapy market is driven by an increase in prevalence of cancer, high R&D investment in gene therapy, and growing awareness concerning gene therapy in particular. Additionally, the untapped potential for emerging markets would create lucrative opportunities for new market players. However, high cost associated with gene therapy and unwanted immune responses as a result of treatment hamper market growth.<\/p>\n

Request Sample Report at: <\/strong>https:\/\/www.alliedmarketresearch.com\/request-sample\/2841<\/strong><\/a><\/p>\n

The report offers an analysis of the market dynamics which include the growth drivers, restraints and opportunities.  Increase in funding for R&D activities pertaining to gene therapy and increase in awareness regarding gene therapy drive the market. Nonetheless, high cost associated with the treatment and unwanted immune responses restrict the growth of the industry. Conversely, increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in prevalence of cancer offer new opportunities for the growth of the market.<\/p>\n

The report offers a broad segmentation of the global gene therapy market. It segments the market into vector type, gene type, applications, and geography. Based on vector type, it is classified into viral vector and non-viral vector. The viral vector segment captured more than half of the market share in 2017 and is likely to remain dominant during the forecast period. The gene type segment is bifurcated into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. The tumor suppressor segment is expected to grow at the fastest CAGR of 35.5% during the study period. The applications segment is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. The oncological disorders segment is likely to dominate in terms of revenue through 2023. The market study covers various geographical locations such as North America, Europe, Asia-Pacific, and LAMEA.<\/p>\n

For Purchase Enquiry:<\/strong> https:\/\/www.alliedmarketresearch.com\/purchase-enquiry\/2841<\/a><\/p>\n

KEY FINDINGS OF GENE THERAPY MARKET STUDY <\/strong> <\/p>\n